7497-89-4

Usage

Uses

Used in Agrochemical Industry:
3-Phenoxy propanoic acid methyl ester is used as an active ingredient in the production of pesticides, herbicides, and insecticides for its ability to effectively control the growth of specific plants and insects, thereby protecting crops and managing pest populations.
Used in Pharmaceutical Industry:
As a chemical intermediate, 3-Phenoxy propanoic acid methyl ester plays a crucial role in the synthesis of various pharmaceutical compounds, contributing to the development of new drugs and therapeutic agents.
Safety Considerations:
Despite its low toxicity, it is essential to exercise proper safety precautions when handling 3-Phenoxy propanoic acid methyl ester to minimize potential health risks and ensure a safe working environment.

InChI:InChI=1/C10H12O3/c1-12-10(11)7-8-13-9-5-3-2-4-6-9/h2-6H,7-8H2,1H3

Upstream product

• 186581-53-3 diazomethane 
• 701-99-5 Phenoxyacetyl chloride 
• 292638-85-8 acrylic acid methyl ester 
• 108-95-2 phenol 
• 67-56-1 methanol 
• 7170-38-9 3-phenoxypropanoic acid 
• 3055-86-5 3-phenoxypropionitrile 
• 6149-41-3 methyl ester (3-hydroxy) propionic acid 
• 71-43-2 benzene 
• 589-10-6 phenoxyethyl bromide 
• 3395-91-3 Methyl 3-bromopropionate 
• 89601-13-8 3-(N-Nitroso-methoxycarbonylamino)-propionsaeure-methylester 

Downstream Products

• 7170-38-9 3-phenoxypropanoic acid 
• 95885-09-9 3-phenoxypropionic acid hydrazide 
• 61904-03-8 1-(3-methyl-3-hydroxy)butoxybenzene 
• 87077-92-7 2-methyl-4-phenoxy-2-butanol 
• 1092473-66-9 methyl 3-(4-(3-methylbutanoyl)phenoxy)propanoate 
• 1016863-79-8 3-phenoxypropionylhydroxamic acid 
• 704-48-3 2,3,4,5-tetrahydro-1,5-benzoxazepin-4-one 
• 1092473-65-8 3-(4-(3-methylbutanoyl)phenoxy)propanoic acid 
• 88579-28-6 ethyl p-[(E)-2-(4,4-dimethyl-6-chromanyl)propenyl]-benzoate 
• 127255-57-6 4-[(Z)-2-(4,4-Dimethyl-chroman-6-yl)-propenyl]-benzoic acid ethyl ester 
• 88579-22-0 [1-(4,4-dimethyl-6-chromanyl)ethyl]triphenylphosphonium bromide 
• 88579-29-7 p-[(E)-2-(3,4-dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)propenyl]benzoic acid 
• 40614-27-5 4,4-dimethylchromane 
• 89709-66-0 3-Phenoxy-propionic acid (3S,8S,9S,10R,13R,14S,17R)-17-((R)-1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester 

Relevant academic research and scientific papers

Palladium-catalyzed aerobic regio- and stereo-selective olefination reactions of phenols and acrylates: Via direct dehydrogenative C(sp2)-O cross-coupling

An efficient olefination protocol for the oxidative dehydrogenation of phenols and acrylates has been achieved using a palladium catalyst and O2 as the sole oxidant. This reaction exhibits high regio- and stereo-selectivity (E-isomers) with mod

Benzene C-H Etherification via Photocatalytic Hydrogen-Evolution Cross-Coupling Reaction

Aryl ethers can be constructed from the direct coupling between the benzene C-H bond and the alcohol O-H bond with the evolution of hydrogen via the synergistic merger of photocatalysis and cobalt catalysis. Utilizing the dual catalyst system consisting of 3-cyano-1-methylquinolinum photocatalyst and cobaloxime, intermolecular etherification of arenes with various alcohols and intramolecular alkoxylation of 3-phenylpropanols with formation of chromanes are accomplished. These reactions proceed at remarkably mild conditions, and the sole byproduct is equivalent hydrogen gas.

METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES

PROBLEM TO BE SOLVED: To provide a method of treating polycystic kidney diseases with ceramide derivatives. SOLUTION: A pharmaceutical composition for treating polycystic kidney disease in a subject comprises an effective amount of a predetermined compoun

Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease

A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject com

Catalytic Olefin hydroalkoxylation by nano particles of pollucite

The catalytic hydroalkoxylation of α,β-unsaturated esters, nitriles, and ethers with aliphatic and aromatic alcohols over pollucite using thermal and microwave-assisted methods was investigated. To study the effect of the alcohol structures on the mechanism of the hydroalkoxylation reaction, different alcohols, such as methanol to butanol, cyclohexanol, phenol, and 2-ethylhexanol were used. The activities of pollucite, in contrast to other basic solids, were scarcely affected by the presence of air and moisture. The correlation between alcohol acidity and reaction activity is discussed. The prepared pollucite was characterized by X-ray diffraction, volumetric nitrogen adsorption surface area analysis, and CO2 temperature-programmed desorption. Scanning electron microscopy analysis revealed that the size of the modified nano catalyst particles was under 40nm.

Highly chemo- and regioselective reaction of hydroxybenzenes in acidic ionic liquid

Highly chemo- and regioselective reaction of hydroxybenzenes with α,β-unsaturated compounds in acidic ionic liquid l-butyl-3- methylimidazolium hydrogen sulphate ([BMIM]HSO4) was reported for the first time. A series of oxa-Michael adducts and Friedel-Crafts alkylated products were synthesized with good yields. The acidic ionic liquid could be easily recycled for at least 5 times with only minor loss in activity.

2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof

2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating

HETEROCYCLIC GPR40 MODULATORS

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

Kinetics and mechanism of thermal gas-phase elimination of β-substituted carboxylic acids

3-Phenoxypropanoic acid (1), 3-(phenylthio)propanoic acid (2), and 4-phenylbutanoic acid (3) were pyrolysed between 520 and 682 K. Analysis of the pyrolysates showed the elimination products to be acrylic acid and the corresponding arene. Pyrolysis of ethyl 3-phenoxypropanoate (4) and its methyl analogue (5), ethyl 3-(phenylthio)propanoate (6) and its methyl counterpart (7), and 3-phenoxypropane nitrile (8) were also investigated between 617 and 737 K. The thermal gas-phase elimination kinetics and product analysis are compatible with a thermal retro-Michael reaction pathway involving a four-membered cyclic transition state.